

Supplemental Table 1. MDS- and CVD-specific cause of death according to duration of survival from the time of MDS diagnosis, according to MDS risk group.

MDS Risk Group	Time to Death	Cause of Death	
		MDS/Leukemia	CVD
High	(0, 12] months	67.9%	8.4%
	(12, 36] months	73.0%	7.3%
	(36, 60] months	69.8%	9.9%
	>60 months	45.3%	18.9%
Intermediate	(0, 12] months	48.8%	18.2%
	(12, 36] months	46.9%	19.4%
	(36, 60] months	39.6%	22.1%
	>60 months	30.9%	25.9%
Low	(0, 12] months	32.1%	23.0%
	(12, 36] months	32.6%	24.4%
	(36, 60] months	29.2%	26.0%
	>60 months	24.4%	29.9%

Supplemental Table 2: Cause of death reported according to the duration of survival after MDS diagnosis, within given MDS histologic subgroups, specifically analyzing patients with Del5q, and RARS (enriched for mutations in *SF3B1*).

		COD					
		MDS/Leukemia		CVD		Other	
		N	%	N	%	N	%
Time to Death							
(0, 12] months	del5q	100	59.17	25	14.79	44	26.04
	RARS	134	33.75	93	23.43	170	42.82
	All others	4271	51.35	1371	16.48	2661	32.18
(12, 36] months	del5q	103	57.54	33	18.44	43	24.02
	RARS	175	35.28	116	23.39	205	41.33
	All others	3175	48.99	1171	18.07	2116	32.84
(36, 60] months	del5q	44	53.01	10	12.05	29	34.94
	RARS	124	35.23	91	25.85	137	38.92
	All others	1004	39.07	565	21.98	989	38.74
>60 months	del5q	23	41.07	12	21.43	21	37.50
	RARS	117	31.97	107	29.23	142	38.80
	All others	578	28.56	539	26.63	898	44.72

Supplemental Figure 1: Percentage of deaths attributed to MDS/myeloid leukemia or to CVD according to MDS subtype. Patients with Del5q had more deaths attributed to MDS than patients with RARS or other MDS patients.

